Related Experiment Video
Updated: Jan 20, 2026

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
Published on: May 9, 2018
Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models
Giuseppe Murdaca1, Alessandro Tonacci2, Simone Negrini3
1Clinical Immunology Unit, Department of Internal Medicine, University of Genoa and Ospedale Policlinico San Martino, 16132 Genoa, Italy. giuseppe.murdaca@unige.it.
Introduction:
MiRNAs have been shown to play a crucial role among lung cancer, pulmonary fibrosis, tuberculosis (TBC) infection, and bronchial hypersensitivity, thus including chronic obstructive pulmonary disease (COPD) and asthma. The oncogenic effect of several miRNAs has been recently ruled out. In order to act on miRNAs turnover, antagomiRs have been developed.
Materials And Methods:
The systematic review was conducted under the PRISMA guidelines (registration number is: CRD42019134173). The PubMed database was searched between 1 January 2000 and 30 April 2019 under the following search strategy: (((antagomiR) OR (mirna antagonists) OR (mirna antagonist)) AND ((lung[MeSH Terms]) OR ("lung diseases"[MeSH Terms]))). We included original articles, published in English, whereas exclusion criteria included reviews, meta-analyses, single case reports, and studies published in a language other than English.
Results And Conclusions:
A total of 68 articles matching the inclusion criteria were retrieved. Overall, the use of antagomiR was seen to be efficient in downregulating the specific miRNA they are conceived for. The usefulness of antagomiRs was demonstrated in humans, animal models, and cell lines. To our best knowledge, this is the first article to encompass evidence regarding miRNAs and their respective antagomiRs in the lung, in order to provide readers a comprehensive review upon major lung disorders.
Insights
AntagomiRs effectively reduce specific microRNAs (miRNAs) involved in lung diseases. This review confirms their utility across human, animal, and cell models for various pulmonary conditions.
Area of Science:
- Biochemistry
- Molecular Biology
- Pulmonology
Background:
- MicroRNAs (miRNAs) are key regulators in lung diseases like cancer, fibrosis, tuberculosis, COPD, and asthma.
- Recent findings have challenged the oncogenic role of certain miRNAs.
- AntagomiRs are designed to modulate miRNA turnover.
Purpose of the Study:
- To systematically review the evidence on microRNAs and their corresponding antagomiRs in lung disorders.
- To provide a comprehensive overview of antagomiR efficacy in pulmonary diseases.
Main Methods:
- Systematic review adhering to PRISMA guidelines.
- PubMed database search from January 2000 to April 2019.
- Included original English articles on antagomiRs and lung diseases; excluded reviews and meta-analyses.
Main Results:
- 68 articles met the inclusion criteria.
- AntagomiRs demonstrated efficiency in downregulating target miRNAs.
- Efficacy was confirmed in human studies, animal models, and cell lines.
Conclusions:
- AntagomiRs are effective tools for targeting specific miRNAs in lung disorders.
- This review offers a comprehensive resource on antagomiRs for major lung diseases.
- The findings support the therapeutic potential of antagomiRs in pulmonology.
Related Concept Videos
Lung Capacity
Biological Effects of Radiation
Tonicity in Animals
Tonicity in Animals
Animal Mitochondrial Genetics
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...

